Evidence map›Paper›PMID 39568802›Full record

ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2024

Research Progress of Alternative Polyadenylation in Diseases Related to Glycolipid Metabolism.

Xiyao Yang, Alayi Bolatai, Jiaxin An, Na Wu

Abstract readReview
In one paragraph

Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiyao Yang *Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, 110004, People' s Republic of China.
Alayi Bolatai *Department of Student Affairs, Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, People' s Republic of China.
Jiaxin AnDepartment of Student Affairs, Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, People' s Republic of China.
Na WuDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, 110004, People' s Republic of China.ORCID 0000-0003-1156-3231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With changes in lifestyle, sedentary behavior or lack of physical exercise increases the risk of various glycolipid metabolic disorders. Glycolipid metabolic dysregulation refers to abnormalities in the metabolism of carbohydrates and lipids, including diseases such as diabetes, obesity, and metabolic syndrome. In-depth research into the molecular mechanisms of glycolipid metabolic dysregulation can help develop more effective treatment strategies and preventive measures to prevent the occurrence of long-term complications such as cardiovascular diseases. Alternative polyadenylation (APA) is an important form of RNA modification that helps regulate gene expression and generate protein diversity. This modification can affect processes such as RNA stability, post-transcriptional modification, and translational regulation. Recent studies have confirmed that APA can influence the expression of genes involved in glucose and lipid metabolism, increasing the probability of developing immune, endocrine, and metabolic diseases. The review explains the research progress of APA involvement in various metabolic diseases and explores these mechanisms, providing new insights and directions for novel metabolic disorder treatment strategies.

Indexed as

3’UTRsalternative polyadenylationAPAdiabetesdysfunctionglycolipid metabolic diseasesmetabolismobesity

Identifiers

PMID39568802
PMCPMC11577258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.